Published in Blood on March 02, 2011
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
How I treat HIV-associated lymphoma. Blood (2012) 1.42
Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood (2012) 1.26
HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol (2012) 1.10
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS (2012) 1.07
Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans. Cancer Epidemiol (2014) 0.88
Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol (2012) 0.87
Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev (2013) 0.86
Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. AIDS Res Hum Retroviruses (2011) 0.84
How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood (2014) 0.83
Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis (2014) 0.81
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS (2014) 0.81
Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One (2013) 0.80
[Lymph node pathology - an update]. Pathologe (2013) 0.78
The role of viral co-infection in HIV-associated non-AIDS-related cancers. Curr HIV/AIDS Rep (2015) 0.76
A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis? PLoS One (2014) 0.75
HIV-associated hematologic malignancies: Experience from a Tertiary Cancer Center in India. Indian J Med Paediatr Oncol (2016) 0.75
Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. J Cancer Epidemiol (2016) 0.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ (2007) 8.87
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med (2016) 5.55
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med (2006) 5.43
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA (2002) 4.75
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ (2002) 4.05
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet (2004) 3.96
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol (2004) 3.93
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 3.91
Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ (2008) 3.85
Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol (2002) 3.79
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
(Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol (2004) 3.43
Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health (2012) 3.43
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics (2006) 3.23
Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum (2007) 3.22
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol (2005) 3.18
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06